See more : Black Mountain Acquisition Corp. (BMAC) Income Statement Analysis – Financial Results
Complete financial analysis of Acumen Pharmaceuticals, Inc. (ABOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acumen Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Elekta AB (publ) (EKTA-B.ST) Income Statement Analysis – Financial Results
- BOHAE BREWERY Co., Ltd. (000890.KS) Income Statement Analysis – Financial Results
- Caisse Régionale de Crédit Agricole Mutuel du Languedoc Société coopérative (CRLA.PA) Income Statement Analysis – Financial Results
- Qing Song Health Co.,Ltd. (6931.TWO) Income Statement Analysis – Financial Results
- Aecc Aero-Engine Control Co.,Ltd. (000738.SZ) Income Statement Analysis – Financial Results
Acumen Pharmaceuticals, Inc. (ABOS)
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M |
| Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
| Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.44% | 99.49% |
| Research & Development | 42.32M | 32.36M | 12.31M | 8.00M | 8.58M |
| General & Administrative | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Other Expenses | 0.00 | -11.00K | 51.00K | 0.00 | 0.00 |
| Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Interest Income | 10.21M | 2.39M | 84.00K | 1.00K | 45.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.81M |
| EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -591.78% | -451.27% |
| Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
| Total Other Income/Expenses | 8.77M | 2.38M | -81.02M | 587.00K | -102.00K |
| Income Before Tax | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
| Income Tax Expense | 0.00 | -2.38M | 81.07M | -1.00K | -45.00K |
| Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -510.03% | -463.29% |
| EPS | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| EPS Diluted | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| Weighted Avg Shares Out | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Weighted Avg Shares Out (Dil) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical...
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
CHARLOTTESVILLE, Va. and BASEL, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), has signed a collaboration...
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
Acumen Pharmaceuticals (ABOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
CHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today...
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced...
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports